Tackling the Physiological Barriers for Successful Mesenchymal Stem Cell Transplantation into the Central Nervous System
Overview
Authors
Affiliations
Over the past decade a lot of research has been performed towards the therapeutic use of mesenchymal stem cells (MSCs) in neurodegenerative and neuroinflammatory diseases. MSCs have shown to be beneficial in different preclinical studies of central nervous system (CNS) disorders due to their immunomodulatory properties and their capacity to secrete various growth factors. Nevertheless, most of the transplanted cells die within the first hours after transplantation and induce a neuroinflammatory response. In order to increase the efficacy of MSC transplantation, it is thus imperative to completely characterise the mechanisms mediating neuroinflammation and cell death following MSC transplantation into the CNS. Consequently, different components of these cell death- and neuroinflammation-inducing pathways can be targeted in an attempt to improve the therapeutic potential of MSCs for CNS disorders.
Zhang Z, Pei Y, Zheng Y, Liu Y, Guo Y, He Y Curr Pharm Des. 2024; 30(28):2229-2243.
PMID: 38910274 DOI: 10.2174/0113816128300103240529114808.
Del Pilar C, Garrido-Matilla L, Del Pozo-Filiu L, Lebron-Galan R, Arias R, Clemente D J Neuroinflammation. 2024; 21(1):49.
PMID: 38355633 PMC: 10867997. DOI: 10.1186/s12974-023-03000-8.
Van Breedam E, Ponsaerts P Int J Mol Sci. 2022; 23(13).
PMID: 35806146 PMC: 9266337. DOI: 10.3390/ijms23137140.
Mezzanotte L, Iljas J, Que I, Chan A, Kaijzel E, Hoeben R Cell Transplant. 2018; 26(12):1878-1889.
PMID: 29390874 PMC: 5802635. DOI: 10.1177/0963689717739718.
Hoornaert C, Le Blon D, Quarta A, Daans J, Goossens H, Berneman Z Stem Cells Transl Med. 2017; 6(5):1434-1441.
PMID: 28244236 PMC: 5442707. DOI: 10.1002/sctm.16-0434.